| Autor: |
Takayuki Kobayashi, Saori Kawai, Shinji Ohno, Tomo Osako, Kengo Takeuchi, Akiko Tonooka, Toshimi Takano, Kokoro Kobayashi, Seiichi Mori, Naomi Hayashi, Masumi Yamazaki, Xiaofei Wang, Lina Inagaki, Arisa Ueki, Fumikata Hara, Takayuki Ueno, Mari Hosonaga, Ippei Fukada, Shunji Takahashi, Yukinori Ozaki |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.21203/rs.3.rs-936695/v1 |
| Popis: |
Comprehensive cancer genomic profile (CGP) tests are being implemented under Japanese universal health insurance system. However, the clinical usefulness of CGP test for breast cancer patients has not been evaluated. Of the 310 patients who underwent CGP testing at our institution between November 2019 and April 2021, 35 patients with metastatic breast cancer whose treatment strategy was discussed by our molecular tumor board within the study period were investigated after exclusion of 2 cases that could not be analyzed. The turn-around time, drug accessibility, and germline identification detection were evaluated. The subtype was luminal in 20 patients (57.1%), triple-negative in 12 patients (34.3%), and luminal-HER2 in 3 patients (8.6%). Actionable gene mutations were detected in 30 patients (85.7%), and 7 patients (20.0%) were recommended for clinical trial participation, with the drug administered to 2 patients (5.7%). Three patients (8.6%) died due to disease progression before the test results were disclosed. We report the results of an initial assessment of the utility of CGP testing for patients with metastatic breast cancer under Japanese universal health insurance system. Conducting CGP tests at a more appropriate time could provide patients with greater benefit from treatments based on their specific gene mutations. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
